Armata reports new FDA milestones for AP-SA02 ahead of planned Phase 3 start

Armata Pharmaceuticals reported new regulatory progress for its bacteriophage candidate AP-SA02 alongside second-quarter 2026 financial results. CEO Deborah Birx said the company continues to finalize the activities needed to start a pivotal Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in the second half of 2026.¹ She added that the company recently submitted the Phase 3 protocol to the FDA, responded to the agency's End-of-Phase 2 meeting minutes, and continued advancing manufacturing work in support of that milestone.¹

On regulatory news, the FDA granted Fast Track designation to AP-SA02 for adjunct treatment of complicated bacteremia caused by MSSA or MRSA, which the company said advances AP-SA02 toward a faster path to potential approval and patient access.¹ Separately, the FDA agreed on an Initial Pediatric Study Plan establishing a regulatory framework for evaluating AP-SA02 in pediatric patients up to age 17 with complicated S. aureus bacteremia, the same indication being pursued in adults, with pediatric studies deferred until adult safety and efficacy data are generated in the planned Phase 3 program.¹

On manufacturing, Armata completed four engineering runs of AP-SA02 at its in-house cGMP facility in Los Angeles, with production of clinical trial material for the Phase 3 study as the next planned step.¹

On funding, Armata received $2.5 million in additional non-dilutive funding from the U.S. Department of War, bringing total funding under that award to $28.7 million, intended to support readiness for the planned Phase 3 study.¹

Financially, Armata held approximately $24.0 million of unrestricted cash and cash equivalents as of June 30, 2026, compared with $8.7 million at the end of 2025, an increase primarily reflecting a $25.0 million term loan funded in May 2026, about $2.4 million in net proceeds from its at-the-market program, and about $1.2 million from stock option exercises.¹ Net income for the quarter was $74.1 million, or $2.02 per basic share, compared with a net loss of $16.3 million in the same period last year.¹